Coherus Biosciences Received A Notice From Abbvie On June 6, Alleging A Breach Of Their Settlement And License Agreement, To Which Coherus Responded On June 11, Denying The Allegation; Both Parties Entered Into A Stipulation On June 14, Resolving Coherus's Motion For A Temporary Restraining Order Against Abbvie
Portfolio Pulse from Charles Gross
Coherus Biosciences received a notice from AbbVie alleging a breach of their settlement and license agreement on June 6. Coherus denied the allegation on June 11, and both parties entered into a stipulation on June 14, resolving Coherus's motion for a temporary restraining order against AbbVie.
June 15, 2023 | 10:36 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie alleged a breach of agreement by Coherus Biosciences, which was denied and resolved on June 14.
AbbVie alleged a breach of their settlement and license agreement with Coherus Biosciences. The issue was resolved on June 14, which may not have a significant short-term impact on AbbVie's stock price.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Coherus Biosciences denied AbbVie's allegation of a breach of agreement and resolved the issue on June 14.
Coherus Biosciences denied AbbVie's allegation of a breach of their settlement and license agreement. The issue was resolved on June 14, which may not have a significant short-term impact on Coherus Biosciences' stock price.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50